-
2023-506601-19-00
6
2025-04-15
transplantation
-
2024-517582-16-00
5
2025-04-14
rapid sequence induction in the operating room
-
2023-504180-16-00
5
2025-04-07
Advanced Breast Cancer
-
2024-512633-32-00
4
2025-04-07
Crohn's disease
-
2023-504550-35-00
5
2025-04-03
Atypical Hemolytic Uremic Syndrome (aHUS)
-
2022-501489-24-00
5
2025-03-28
First-line treatment of adult subjects with high-risk large B-cell lym
-
2024-513550-30-00
5
2025-03-28
Newly diagnosed Glioblastoma
-
2023-504086-23-00
5
2025-03-27
Subjects with PBC with a non-optimal response to UDCA.
-
2024-512729-10-00
4
2025-03-27
Recurrent or metastatic solid cancer harboring a FGFR1,2 ,3 fusion/rea
-
2023-507937-14-00
7
2025-03-25
Metastatic Solid Tumor
-
2024-515861-33-00
4
2025-03-25
Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, an
-
2023-508307-21-00
5
2025-03-19
Prader-Willi syndrome
-
2024-513285-19-00
1
2025-03-14
Pancreatic Ductal Adeno Carcinoma
-
2024-511821-75-00
7
2025-03-13
Crohn’s fistula
-
2024-513547-82-00
5
2025-03-11
Transthyretin Amyloidosis
-
2024-513443-93-00
4
2025-03-10
Recurrent Meningioma without local treatment options (Surgery or Radio
-
2023-505291-30-01
4
2025-03-06
Triple Negative Breast Cancer with residual disease after neoadjuvant
-
2023-510079-74-00
5
2025-03-06
meniscal pain of degenerative origin
-
2023-507873-16-00
11
2025-03-04
1st line treatment for unresectable metastatic colorectal cancer
-
2023-510292-65-00
5
2025-02-25
chronic graft-versus-host disease
-
2023-509787-15-00
5
2025-02-17
Patients with localised prostate cancer and high-risk features of rela
-
2023-508798-94-00
5
2025-02-11
Heart failure
-
2023-509632-26-00
9
2025-02-11
Recurrent or Metastatic Solid Tumors (endometrial cancer (EC); head an
-
2023-509146-35-00
6
2025-01-30
Systemic Lupus Erythematosus